The Proteomics Core Facility at Oslo University Hospital (Rikshospitalet)
Proteomics Core Facility at OUH-Rikshospitalet The Proteomics Core Facility (PCF) at Oslo University Hospital – Rikshospitalet provides proteomic service to all research groups in the HSØ region in need of it. We are constantly expanding our service portfolio to serve the increasing demands for such analysis. New techniques and expertise are made available as service regularly. As it happened in previous years, demands for service in 2014 had increased considerably. A consequence of this was that instrument waiting queue has been on average 6 weeks, with peaks of 8 weeks waiting just before the summer months. This demonstrates that the level of acceptance of the PCF and data feedback to users (and therefore, their return with new samples) has been excellent. Part of this success is due to the implementation of the high-resolution mass spectrometer acquired in April 2012. By December 2014, this instrument alone recorded its 7500th sample injection since installation, meaning that the instrument had been booked and in use around 82% of available hours in both years, even considering maintenance downtime. As occurred in 2013, failures in the nano-LC system coupled to the instrument have been our major bottleneck; we believe now it is our utmost priority to acquire a backup LC system to reduce downtime. Early 2014 the PCF was also granted funds to acquire a new high resolution instrument through an UiO Infrastructure call. A new QExactive Plus was installed at PCF in late November 2014. PCF therefore doubled its sample capacity and a decrease in waiting is expected for the users. Another considerable investment by PCF in early 2014 was the acquisition of a rack server from Dell with 64 processing cores, to allow faster data analyses. User experiments that previously requested over two weeks of computational time to process mass spec data, now requires less than 48 hours. Licenses from software packages described in previous reports were extended for 2014/15. All objectives set for projects supporting the application were achieved and publications are being prepared by the collaborators with support from PCF. Finally, from May 2014 PCF started charging its users for instrument time and data analysis. Prices can be found at the PCF website http://core.ous-research.no/index.php?section=204
Different binding motifs of the celiac disease-associated HLA molecules DQ2.5, DQ2.2, and DQ7.5 revealed by relative quantitative proteomics of endogenous peptide repertoires.
Immunogenetics 2015 Feb;67(2):73-84. Epub 2014 des 12
Identification of rare alternative splicing events in MS/MS data reveals a significant fraction of alternative translation initiation sites.
PeerJ 2014;2():e673. Epub 2014 nov 13
HLA-DQ molecules as affinity matrix for identification of gluten T cell epitopes.
J Immunol 2014 Nov 1;193(9):4497-506. Epub 2014 sep 26
Nasal and ocular amyloidosis in a 15-year-old horse.
Acta Vet Scand 2014;56():50. Epub 2014 aug 27
Characterization of amyloid in equine recurrent uveitis as AA amyloid.
J Comp Pathol 2014 Aug-Oct;151(2-3):228-33. Epub 2014 jun 26
Assessing the citrullinome in rheumatoid arthritis synovial fluid with and without enrichment of citrullinated peptides.
J Proteome Res 2014 Jun 6;13(6):2867-73. Epub 2014 apr 28
Search for novel targets of the PII signal transduction protein in Bacteria identifies the BCCP component of acetyl-CoA carboxylase as a PII binding partner.
Mol Microbiol 2014 Feb;91(4):751-61. Epub 2014 jan 6
Identification of peptide products from enzymatic degradation of amyloid beta.
Biochimie 2014 Oct;105():216-20. Epub 2014 jul 7
Using SILAC proteomics to investigate the effect of the mycotoxin, alternariol, in the human H295R steroidogenesis model.
Cell Biol Toxicol 2014 Dec;30(6):361-76. Epub 2014 nov 22